Commentary: osteoarthritis of the knee and glucosamine

Osteoarthritis and Cartilage

Volumn 14, Issue 10, 2006, Pages 963-966

  Altman, R D ^a   Abramson, S ^b   Bruyere, O ^c   Clegg, D ^d   Herrero Beaumont, G ^e   Maheu, E ^f   Moskowitz, R ^g   Pavelka, K ^h   Reginster, J Y ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f HÔPITAL SAINT ANTOINE   (France)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

Author keywords

Chondroitin sulfate; Clinical trials; Commentary; GAIT; Glucosamine; GUIDE; Knee; Osteoarthritis

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CHONDROITIN SULFATE; CYCLOOXYGENASE 2 INHIBITOR; GLUCOSAMINE; GLUCOSAMINE SULFATE; IBUPROFEN; INTERLEUKIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTAGLANDIN E2;

ANALGESIA; ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG LABELING; DRUG MECHANISM; EUROPE; EVIDENCE BASED MEDICINE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEALTH CARE ORGANIZATION; HUMAN; INHIBITION KINETICS; KNEE OSTEOARTHRITIS; KNEE PAIN; KNEE RADIOGRAPHY; MEDICAL RESEARCH; METHODOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 33748155668     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2006.06.010     Document Type: Note

References (33)

1. van Saase J.L., van Romunde L.K., Cats A., Vandenbroucke J.P., and Valkenburg H.A. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 48 (1989) 271-280
2. Carmona L., Ballina J., Gabriel R., and Laffon A. EPISER Study Group. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60 (2001) 1040-1045
3. Le Pen C., Reygrobellet C., and Gerentes I. Financial cost of osteoarthritis in France. The "COART" France study. Joint Bone Spine 72 (2005) 567-570
4. Lawrence R.C., Helmick C.G., Arnett F.C., Deyo R.A., Felson D.T., Giannini E.H., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41 (1998) 778-799
5. Bolen J., Helmick C.G., Sacks J.J., and Langmaid G. Prevalence of self-reported arthritis or chronic joint symptoms among adults-United States, 2001. MMWR Morb Mortal Wkly Rep 51 (2002) 948-950
6. Hochberg M.C., Altman R.D., Brandt K.D., Clark B.M., Dieppe P.A., Griffin M.R., et al. Guidelines for the medical management of osteoarthritis, part II. Osteoarthritis of the knee. Arthritis Rheum 38 (1995) 1541-1546
7. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines, Altman R.D., Hochberg M.C., Moskowitz R.W., and Schnitzer T.J. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43 (2000) 1905-1915
8. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62 (2003) 1145-1155
9. Breivik H., Collett B., Ventafridda V., Cohen R., and Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain (2005 Aug 8) [Epub ahead of print]
10. Towheed T.E., Maxwell L., Anastassiades T.P., Shea B., Houpt J., Robinson V., et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2 (2005 Apr 18) CD002946
11. Biggee B.A., and McAlindon T. Glucosamine for osteoarthritis: part I, review of the clinical evidence. Med Health R I 87 (2004) 176-179
12. Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y., and Reginster J.Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 163 (2003) 1514-1522
13. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate and the two in combination for painful knee osteoarthritis. N Engl J Med 354 (2006) 795-808
14. Pham T., van der Heijde D., Altman R.D., Anderson J.J., Bellamy N., Hochberg M., et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 12 (2004) 389-399
15. Herrero-Beaumont G., Roman J.A., Trabado M.C., Blanco F.J., Benito P., Martin-Mola E., et al. Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms vs placebo and acetaminophen: results from the Glucosamine Unum in Die Efficacy (GUIDE) trial. Arthritis Rheum 52 (2005) S460
16. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357 (2001) 251-256
17. Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacovelli G., and Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162 (2002) 2113-2123
18. Bruyere O., Compere S., Rovati L.C., Giacovelli G., Deroisy R., and Reginster J.-Y. Five-year follow-up of patients from a previous 3-year randomized, controlled trial of glucosamine sulfate in knee osteoarthritis. Arthritis Rheum 48 (2003) S80
19. Pavelka K., Gatterova J., Giacovelli G., Olejarova M., and Rovati L.C. Glucosamine sulfate prevents total joint replacement in the long-term followup of knee osteoarthritis in patients. Osteoarthritis Cartilage 13 Suppl B (2005) S74
20. Mazzuca S.A., Brandt K.D., Lane K.A., and Katz B.P. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 46 (2002) 1223-1227
21. Pavelka K., Bruyere O., Rovati L.C., Olejarova M., Giacovelli G., and Reginster J.Y. Relief in mild-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. Osteoarthritis Cartilage 11 (2003) 730-737
22. Biggee B.A., Blinn C.M., McAlindon T.E., Nuite M., and Silbert J.E. Low levels of human serum glucosamine after ingestion of glucosamine relative to capability for peripheral effectiveness. Ann Rheum Dis 65 (2006) 222-226 10.1136/ard.2005.036368
23. Laverty S., Sandy J.D., Celeste C., Vachon P., Marier J.F., and Plaas A.H. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum 52 (2005) 181-191
24. Persiani S., Roda E., Rovati L.C., Locatelli M., Giacovelli G., and Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 13 (2005) 1041-1049
25. Persiani S., Rotini R., Trisolino G., Delliponti L., Rovati L.C., Locatelli M., et al. Glucosamine plasma and synovial fluid concentrations before and after oral administration of crystalline glucosamine sulfate in knee osteoarthritis patients. Arthritis Rheum 52 (2005) S508
26. Piepoli T., Zanelli T., Letari O., Persiani S., Rovati L.C., and Caselli G. Glucosamine inhibits IL-1-stimulated gene expression at concentrations found in human plasma after oral intake. Osteoarthritis Cartilage 13 Suppl A (2005) S151
27. Jackson C.G., Plaas A.H., Barnhill J.G., Harris C.L., and Clegg D.O. The pharmacokinetics of oral glucosamine and chondroitin sulfate in humans. Arthritis Rheum 52 (2005) 4062-4063 (Abstract)
28. Largo R., Alvarez-Soria M.A., Diez-Ortego J., Calvo E., Sanchez-Pernaute O., Egido J., et al. Glucosamine inhibits IL-1 beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 11 (2003) 290-298
29. Alvarez-Soria M.A., Largo R., Calvo E., Egido J., and Herrer-Beaumont G. Differential anticatabolic profile of glucosamine sulfate versus other anti-osteoarthritic drugs on human osteoarthritic chondrocytes and synovial fibroblasts in culture. Osteoarthritis Cartilage 13 (2005) S153
30. van Osch G., Uitterlinden E.J., Koevoet W.L.M., DeGroot J., Vefhaar J.A.N., and Weinans H. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage 14 (2006 March)
31. Russell A.S., Aghazadeh-Habashi A., and Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 29 (2002) 2407-2409
32. Hoffer L.J., Kaplan L.N., Hamadeh M.J., Grigoriu A.C., and Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 50 (2001) 767-770
33. Cordoba F., and Nimni M.E. Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthritis Cartilage 11 (2003) 228-230